What LEVI-04 data suggest about the future of disease-modifying osteoarthritis therapies
LEVI-04 Phase II data from Levicept Ltd. signal a shift in osteoarthritis treatment. Discover what this means for disease-modifying therapies.
Can low-dose radiotherapy reshape osteoarthritis care after Siemens Healthineers’ FDA clearance
Siemens Healthineers expands TrueBeam into osteoarthritis care with FDA clearance. Find out how radiotherapy could reshape chronic pain treatment.